What if half the population’s health needs were an afterthought in global innovation—and what if fixing that presented a hundred-billion-dollar opportunity? Femtech is no longer just about fertility apps; it’s redefining how healthcare serves women across every stage of life. This report dives deep into the data behind the momentum, the money, and the massive market gaps that innovators and investors can no longer afford to ignore.
What if the untapped health needs of half the global population represented a $100B opportunity? Femtech is evolving from niche fertility tools into a powerful driver of inclusive innovation in healthcare. This comprehensive Femtech investment report explores the sector’s rapid evolution, spotlighting high-growth trends, persistent funding inequities, and the pressing need for health equity.
Backed by HealthTech Alpha—Galen Growth’s proprietary platform for global digital health data and market intelligence—this Femtech investment report delivers unmatched, non-hyped, data-driven insights across the ecosystem. From startup traction to investor dynamics, it’s an essential resource for those looking to understand where innovation is happening—and where it’s falling short.
The “Femtech Challenge” report includes data on the following companies: Freya Biosciences, Millie, Allara, Orange Health, Oula, Flo Health, Freenome, BillionToOne, Koios Medical, Maven, Foodsmart, Sword Health, Eko Health, BillionToOne, Willow, RH Capital, Amboy Street Ventures, The Case for Her , Great Oaks Venture Capital, The Gates Foundation, GV, General Catalyst
Femtech’s Challenge: Growth, Gaps, and the Health Equity Imperative report is powered by HealthTech Alpha, the premier digital health intelligence platform delivering unparalleled data and insights into the evolving healthcare technology landscape. Leveraging an extensive database of over 15,000 ventures and cutting-edge analytics, HealthTech Alpha provides a data-driven foundation to analyse the critical trends shaping the future of digital health.
Designed to empower stakeholders—including investors, pharmaceutical leaders, and medical device manufacturers—HealthTech Alpha offers actionable intelligence to navigate digital transformation complexities. This collaboration ensures readers gain a comprehensive, evidence-based view of the intersection between digital health and healthcare, equipping them to identify strategic opportunities, assess market dynamics, and stay ahead in this fast-evolving industry.
Our Premium Reports are specialized reports that are only available to active users with HealthTech Alpha Pro and HealthTech Alpha Enterprise accounts and are provided at no additional cost.
Galen Growth’s proprietary platform, HealthTech Alpha, provides the data source for this report. Corporate Business Development, Business Intelligence, and Digital Health Partnership teams worldwide prefer HealthTech Alpha, the world’s most-trusted Digital Health data, intel, and insights platform. Visit https://www.healthtechalpha.com to learn more about our data or https://www.galengrowth.com research for our reports.
Founded in 2016 by Digital Health experts, Galen Growth empowers global Fortune 500 companies, institutional investors, and promising Digital Health ventures to fast track their digital health strategy to create significant financial and social values. To find out more, visit https://www.galengrowth.com
| Pages | Description | Content |
|---|---|---|
| 2-9 | Introduction | – |
| 10-23 | Femtech’s Challenge | 9 charts, 3 tables |
| 24-32 | Ecosystem Insights | 12 charts, 2 tables |
| 33-42 | Investment Insights | 9 charts, 4 tables |
| 43-48 | Cluster Focus | 3 charts, 2 tables |
| 49-55 | Therapeutic Focus | 5 charts, 2 tables |
| 56-72 | Regional Snapshots | 21 charts, 3 tables |
| 73-80 | Key Information | – |
